Even when a clot is successfully removed after an ischemic stroke, millions of patients still face devastating neurological disability. A growing body of evidence suggests that what happens in the operating suite during that intervention — the anesthetic choice, the inflammatory response it triggers, and the immune cascades it may dampen or amplify — could be just as consequential as the procedure itself. That realization is beginning to reshape how stroke specialists think about perioperative care.
An international multidisciplinary expert group publishing in Stroke synthesized preclinical and clinical evidence on immunomodulatory strategies applicable during the perioperative window of endovascular thrombectomy (EVT). The consensus identifies two intertwined problems that limit recovery even after successful vessel recanalization: the no-reflow phenomenon, in which microvascular obstruction persists despite macrovascular clearance, and post-ischemic neuroinflammation, driven by innate immune activation, complement cascades, and blood-brain barrier disruption. The review evaluates how anesthetic regimens — general anesthesia versus conscious sedation — differentially modulate these pathways, and whether adjunctive immunotherapies administered perioperatively could improve long-term functional outcomes.
This consensus arrives at a pivotal moment in stroke neuroscience. Recanalization rates with modern EVT now exceed 80% in many centers, yet roughly half of treated patients still fail to achieve functional independence at 90 days. This gap has shifted scientific attention upstream, toward the biological environment in which reperfusion occurs rather than reperfusion itself. The perioperative window represents a largely underexplored therapeutic frontier: immune interventions timed to coincide with the reperfusion event could theoretically attenuate the ischemia-reperfusion injury amplified by sudden restoration of blood flow. However, the evidence base remains primarily preclinical, with heterogeneous animal models that do not reliably translate to human stroke pathophysiology. The consensus format, while valuable for harmonizing expert opinion and identifying research gaps, does not substitute for large randomized controlled trials. Its greatest contribution may be catalyzing the trial design infrastructure needed to test specific perioperative immune strategies in well-defined patient populations.